# Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery

> **NCT05169866** · PHASE3 · RECRUITING · sponsor: **Beijing Anzhen Hospital** · enrollment: 274 (estimated)

## Conditions studied

- New Onset Atrial Fibrillation
- Complications; Cardiac, Postoperative

## Interventions

- **DRUG:** Nifekalant
- **DRUG:** Amiodarone

## Key facts

- **NCT ID:** NCT05169866
- **Lead sponsor:** Beijing Anzhen Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-29
- **Primary completion:** 2025-05
- **Final completion:** 2025-06
- **Target enrollment:** 274 (ESTIMATED)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169866, "Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05169866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*